Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninerafaxstat in Type 2 Diabetes and HFpEF (IMPROVE-DiCE)
NCT04826159Phase 2Completed
- Sponsor
- Imbria Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ninerafaxstat in diabetic cardiomyopathy (DCM), heart failure with preserved ejection fraction (HFpEF), type 2 diabetes mellitus (T2DM), sponsored by Imbria Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
ninerafaxstat
03
Conditions
diabetic cardiomyopathy (DCM)heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04826159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826159.